Literature DB >> 22227125

Cannabinoid receptor CB2 protects against balloon-induced neointima formation.

Filippo Molica1, Christian M Matter, Fabienne Burger, Graziano Pelli, Sébastien Lenglet, Andreas Zimmer, Pal Pacher, Sabine Steffens.   

Abstract

Cannabinoid receptor CB(2) activation inhibits inflammatory proliferation and migration of vascular smooth muscle cells in vitro. The potential in vivo relevance of these findings is unclear. We performed carotid balloon distension injury in hypercholesterolemic apolipoprotein E knockout (ApoE(-/-)) mice receiving daily intraperitoneal injection of the CB(2) agonist JWH133 (5 mg/kg) or vehicle, with the first injection given 30 min before injury. Alternatively, we subjected CB(2)(-/-) and wild-type (WT) mice to balloon injury. We determined CB(2) mRNA and protein expression in dilated arteries of ApoE(-/-) mice. Neointima formation was assessed histologically. We used bone marrow-derived murine CB(2)(-/-) and WT macrophages to study adhesion to plastic, fibronectin, or collagen, and migration was assayed by modified Boyden chamber. Aortic smooth muscle cells were isolated to determine in vitro proliferation rates. We found increased vascular CB(2) expression in ApoE(-/-) mice in response to balloon injury. Seven to twenty-one days after dilatation, injured vessels of JWH133-treated mice had less intimal nuclei numbers as well as intimal and medial areas, associated with less staining for proliferating cells, smooth muscle cells, and macrophages. Complete endothelial repair was observed after 14 days in both JWH133- and vehicle-treated mice. CB(2) deficiency resulted in increased intima formation compared with WT, whereas JWH133 did not affect intimal formation in CB(2)(-/-) mice. Apoptosis rates assessed by in situ terminal deoxynucleotidyl transferase dUTP-mediated nick-end labeling staining 1 h postballooning were significantly higher in the CB(2) knockouts. In vitro, bone marrow-derived CB(2)(-/-) macrophages showed enhanced adherence and migration compared with WT cells and elevated mRNA levels of adhesion molecules, chemokine receptors CCR1 and 5, and chemokine CCL2. Proliferation rates were significantly increased in CB(2)(-/-) smooth muscle cells compared with WT. In conclusion, pharmacological activation or genetic deletion of CB(2) receptors modulate neointima formation via protective effects in macrophages and smooth muscle cells.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22227125      PMCID: PMC3774259          DOI: 10.1152/ajpheart.00444.2011

Source DB:  PubMed          Journal:  Am J Physiol Heart Circ Physiol        ISSN: 0363-6135            Impact factor:   4.733


  41 in total

Review 1.  CB2 receptor-mediated migration of immune cells: it can go either way.

Authors:  A M Miller; N Stella
Journal:  Br J Pharmacol       Date:  2007-11-05       Impact factor: 8.739

Review 2.  Chemokines in vascular dysfunction and remodeling.

Authors:  Andreas Schober
Journal:  Arterioscler Thromb Vasc Biol       Date:  2008-09-25       Impact factor: 8.311

Review 3.  Cannabinoid CB2 receptors: a therapeutic target for the treatment of inflammatory and neuropathic pain.

Authors:  J Guindon; A G Hohmann
Journal:  Br J Pharmacol       Date:  2007-11-12       Impact factor: 8.739

Review 4.  The emerging role of the endocannabinoid system in cardiovascular disease.

Authors:  Pál Pacher; Sabine Steffens
Journal:  Semin Immunopathol       Date:  2009-04-09       Impact factor: 9.623

Review 5.  Drug-eluting stents - what should be improved?

Authors:  Jan Steffel; Franz R Eberli; Thomas F Lüscher; Felix C Tanner
Journal:  Ann Med       Date:  2008       Impact factor: 4.709

6.  CB2 cannabinoid receptor agonist JWH-015 modulates human monocyte migration through defined intracellular signaling pathways.

Authors:  Fabrizio Montecucco; Fabienne Burger; François Mach; Sabine Steffens
Journal:  Am J Physiol Heart Circ Physiol       Date:  2008-01-04       Impact factor: 4.733

Review 7.  Cannabinoid CB2 receptors in the gastrointestinal tract: a regulatory system in states of inflammation.

Authors:  K L Wright; M Duncan; K A Sharkey
Journal:  Br J Pharmacol       Date:  2007-10-01       Impact factor: 8.739

8.  The cannabinoid receptor type 2 promotes cardiac myocyte and fibroblast survival and protects against ischemia/reperfusion-induced cardiomyopathy.

Authors:  Nicole Defer; Jinghong Wan; Richard Souktani; Brigitte Escoubet; Magali Perier; Philippe Caramelle; Sylvie Manin; Vanessa Deveaux; Marie-Claude Bourin; Andreas Zimmer; Sophie Lotersztajn; Françoise Pecker; Catherine Pavoine
Journal:  FASEB J       Date:  2009-02-26       Impact factor: 5.191

9.  CB(2) cannabinoid receptor activation is cardioprotective in a mouse model of ischemia/reperfusion.

Authors:  Fabrizio Montecucco; Sébastien Lenglet; Vincent Braunersreuther; Fabienne Burger; Graziano Pelli; Maria Bertolotto; François Mach; Sabine Steffens
Journal:  J Mol Cell Cardiol       Date:  2009-01-07       Impact factor: 5.000

Review 10.  The endocannabinoid system: its general strategy of action, tools for its pharmacological manipulation and potential therapeutic exploitation.

Authors:  Vincenzo Di Marzo
Journal:  Pharmacol Res       Date:  2009-03-04       Impact factor: 7.658

View more
  8 in total

Review 1.  The Role of Inflammation in Cardiovascular Outcome.

Authors:  Fabrizio Montecucco; Luca Liberale; Aldo Bonaventura; Alessandra Vecchiè; Franco Dallegri; Federico Carbone
Journal:  Curr Atheroscler Rep       Date:  2017-03       Impact factor: 5.113

2.  Targeting cannabinoid receptor CB(2) in cardiovascular disorders: promises and controversies.

Authors:  Sabine Steffens; Pál Pacher
Journal:  Br J Pharmacol       Date:  2012-09       Impact factor: 8.739

3.  Identification of a stable molecular signature in mammary tumor endothelial cells that persists in vitro.

Authors:  Lin Xiao; J Chuck Harrell; Charles M Perou; Andrew C Dudley
Journal:  Angiogenesis       Date:  2013-11-21       Impact factor: 9.596

4.  Cannabinoid receptor 2 activation alleviates diabetes-induced cardiac dysfunction, inflammation, oxidative stress, and fibrosis.

Authors:  Mohanraj Rajesh; Partha Mukhopadhyay; Sándor Bátkai; Muhammad Arif; Zoltán V Varga; Csaba Mátyás; Janos Paloczi; Andrea Lehocki; György Haskó; Pal Pacher
Journal:  Geroscience       Date:  2022-04-22       Impact factor: 7.581

Review 5.  Cardiovascular effects of marijuana and synthetic cannabinoids: the good, the bad, and the ugly.

Authors:  Pal Pacher; Sabine Steffens; György Haskó; Thomas H Schindler; George Kunos
Journal:  Nat Rev Cardiol       Date:  2017-09-14       Impact factor: 32.419

6.  Endogenous cannabinoid receptor CB1 activation promotes vascular smooth-muscle cell proliferation and neointima formation.

Authors:  Filippo Molica; Fabienne Burger; Aurélien Thomas; Christian Staub; Anne Tailleux; Bart Staels; Graziano Pelli; Andreas Zimmer; Benjamin Cravatt; Christian M Matter; Pal Pacher; Sabine Steffens
Journal:  J Lipid Res       Date:  2013-03-11       Impact factor: 5.922

7.  Nanoparticle-Mediated Targeting of Cyclosporine A Enhances Cardioprotection Against Ischemia-Reperfusion Injury Through Inhibition of Mitochondrial Permeability Transition Pore Opening.

Authors:  Gentaro Ikeda; Tetsuya Matoba; Yasuhiro Nakano; Kazuhiro Nagaoka; Ayako Ishikita; Kaku Nakano; Daiki Funamoto; Kenji Sunagawa; Kensuke Egashira
Journal:  Sci Rep       Date:  2016-02-10       Impact factor: 4.379

8.  Treatment with CB2 agonist JWH-133 reduces histological features associated with erectile dysfunction in hypercholesterolemic mice.

Authors:  Rodrigo Araujo Fraga-Silva; Fabiana Pereira Costa-Fraga; Fabrizio Montecucco; Younouss Faye; Silvia Quintao Savergnini; Sébastien Lenglet; François Mach; Sabine Steffens; Nikolaos Stergiopulos; Robson Augusto Souza dos Santos; Rafaela Fernandes da Silva
Journal:  Clin Dev Immunol       Date:  2013-11-03
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.